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Abstract 
Background: When curative treatments are no longer available for cancer patients, the aim of treatment is palliative. 
The emphasis of palliative care is on optimizing quality of life and provided support for patients nearing end of life. 
However, chemotherapy is often offered as a palliative therapy for patients with advanced cancer nearing death. The 
purpose of this review was to evaluate the state of the science relative to use of palliative chemotherapy and mainte-
nance of quality of life in patients with advanced cancer who were at end of life.
Materials and methods: Published research from January 2010 to December 2019 was reviewed using PRISMA 
guidelines using PubMed, Proquest, ISI web of science, Science Direct, and Scopus databases. MeSH keywords includ-
ing quality of life, health related quality of life, cancer chemotherapy, drug therapy, end of life care, palliative care, 
palliative therapy, and palliative treatment.
Findings: 13 studies were evaluated based on inclusion criteria. Most of these studies identified that reduced quality 
of life was associated with receipt of palliative chemotherapy in patients with advanced cancer at the end of life.
Conclusion: Studies have primarily been conducted in European and American countries. Cultural background of 
patients may impact quality of life at end of life. More research is needed in developing countries including Mideast-
ern and Asian countries.
Keywords: Quality of life (QOL), Health related quality of life (HRQOL), Cancer chemotherapy, Drug therapy, End of 
life care, Palliative care, Palliative therapy, Palliative treatment
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Introduction
Best practices for management of advanced cancer are of 
global health concern, particularly in developing coun-
tries [1]. When curative strategies are exhausted, the 
focus of cancer care shifts to maintenance of quality of 
life (QOL) and extension of survival [2]. Studies indi-
cate that – 20 to 50% of patients with advanced cancers 
receive chemotherapy (CT) towards end of life with the 
aims of extending survival and improving QOL [3–5]. 
Such rigorous treatment strategies may contribute to 
death in non-preferred environments such as the inten-
sive care unit (ICU), incurring additional costs for care 
that is often futile and that may also diminish QOL in 
the patients’ final days. Intensive medical management 
at end of life may also limit the opportunity for patients 
to receive hospice services, supportive care that focuses 
on enhancing comfort and promoting quality of life when 
facing death [6]. The purpose of the review was to exam-
ine the state of the science relative to the use of CT in 
patients with advanced cancers at the end of life, and to 
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evaluate the impact of such treatments on patients QOL 
as they near death.
Chemotherapy generally refers to treatments aimed at 
stopping or eradicating the growth of cancer cells that are 
administered orally, intravenously, intrathecally, by injec-
tion, or subcutaneously depending on the type and stage 
of cancer being treated [7]. For patients with advanced 
cancers, many are now receiving oral antineoplastic 
agents [8]. Chemotherapies (CT) in general are associ-
ated with a host of side effects and symptoms that are 
specific to the type of agent and individualized patient 
characteristics. Numerous studies have identified the 
impact of CT on QOL, with some research suggesting 
that patients may experience improved QOL and length 
of survival when offered such treatments as a last alterna-
tive [9]. However, CT are also associated with increasing 
the cost of care at end of life due to the additional costs 
associated with need for pharmaceuticals, potential for 
blood products, laboratory and diagnostic testing, health 
professional support and unscheduled visits that result in 
hospitalization [10, 11].
Palliative care is aimed at providing comprehen-
sive support and comfort via a multidisciplinary team 
approach to enhance QOL when cure is not an option 
[12]. Some research has shown that stoppage of intensive 
medical treatments and providing palliative care have 
improved both QOL and length of survival of advanced 
cancer patients [13]. Further, the incorporation of early 
specialized palliative care may reduce the risk of receiv-
ing CT during the final two weeks of life [14]. Many 
patients who have good performance status, however, 
receive palliative CT as they near end of life with the aim 
of increasing survival length and even to improve QOL 
[10].
According to the Health Service Research Committee 
of the American Society of Clinical Oncology (ASCO), 
CT can potentially improve QOL in late stages of life 
even if it doesn’t impact survival length [13]. Further, 
medical decision making relative to use of CT in patients 
nearing the end of life may be fostered by the develop-
ment and availability of newer anticancer agents that have 
fewer side effects [15]. However, ASCO and the National 
Quality Forum have identified that other factors impact 
QOL at end of life (defined as final 30  days of life) and 
should be considered, such as unscheduled emergency 
room visits, the potential for lengthy hospitalizations, 
ICU admissions, and ICU deaths [16]. Recently, ASCO 
contended that stopping CT in cancer patients at the end 
of life is one of five factors which can improve the qual-
ity of patient care and reduce healthcare costs [16]. There 
remain limited studies that have systematically evaluated 
the effects of palliative CT on the QOL of cancer patients 
nearing end of life [4, 16, 17]. Some studies evaluate 
factors such as age, sex, type of cancer, and health care 
system characteristics while omitting information about 
perceived QOL [14]. Research findings suggest that cul-
ture may impact the utilization of aggressive treatment 
in patients with advanced cancer. For example, a study 
from Japan stated that only 3.7% of patients receive CT in 
their last 2 weeks of life [18]. In spite of increasing use of 
CT at end of life in recent years, the impact on patients’ 
QOL remains equivocal. Therefore, the purpose of this 
review was to evaluate what is known about the use of 
CT and associated QOL in patients with advanced can-
cer approaching end of life.
Methods
Research question
The research question aimed to examine: what is the state 
of the science between use of palliative CT and QOL in 
patients with advanced cancer at end of life?
Search strategy
An integrative review was conducted in 2019. Studies 
published between January 2010 and December 2019 
were reviewed using PRISMA guidelines (see Fig. 1). Six 
databases (PubMed, Proquest, ISI web of science, Science 
Direct, Scopus, SID) were searched using AND and OR 
Boolean operators. MeSH keywords including quality of 
life (QOL), health related quality of life (HRQOL), can-
cer chemotherapy, drug therapy, end of life care, pallia-
tive care, palliative therapy, and palliative treatment were 
used to search for associated studies.
Eligibility criteria
Inclusion criteria were: (1) Persian and English articles 
published between January 2010 to December 2019 that 
were freely accessible; (2) patients with advanced cancer 
at the end of life; (3) evaluation of anti-cancer CT and 
patients’ QOL; and (4) quantitative data based (includ-
ing retrospective, prospective cohort, cross-sectional 
studies,). Exclusion criteria were studies that evaluated 
specific CT regimens without an inquiry of patients’ 
QOL, and use of other treatment modalities in conjunc-
tion with CT. Also eliminated were interventional stud-
ies that did not address the relationships between use of 
palliative CT and QOL in patients with advanced cancer 
nearing end of life. The Boolean operators like OR (for 
synonymous keywords) and AND (for relating different 
keywords) was performed to search the articles. Utiliz-
ing these established inclusion and exclusion criteria, 
abstracts of retrieved articles were first reviewed and 
those that matched the criteria were evaluated. After 
duplicates were removed, two researchers indepen-
dently reviewed the included articles and concurrence 
was achieved with 13 papers finally selected. The search 
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results are presented in Table  1. The steps for choosing 
articles based on PRISMA guidelines are also shown in 
Fig. 1.
Quality assessment (risk of bias)
The quality of the studies was separately measured by 
two researchers using two tools, the Quality Assessment 
of Diagnostic Accuracy Studies (QUADAS-2) and the 
checklist of Standards for Reporting of Diagnostic Accu-
racy (STARD) [19]. These tools examine the risk bias in 
accuracy and comprehensiveness of study reports. The 
combination of both tools, with revision of some cases, 
improved the examination of the included studies [20]. 
QUADAS-2 was used to measure the internal stability of 
the studies studied. The tool consists of items with three-
option answers (i.e., yes, no, and unknown). A 25-item 
STARD tool was used to evaluate the study design quality 
(including sample collection and data). The combination 
of these two tools and their associated flexibility helped 
make them compatible with the study goals [20]. Stand-
ardized methods were used to ensure the quality assess-
ment and to ensure the inter-rater reliability of both 
analyses. Finally, findings from the two assessments were 
evaluated to ensure that they were comparable [21].
Results
Of the 13 studies, five studies were conducted in the 
United States (U.S.), six were from Europe, and one were 
from Australia and India respectively. Based on stud-
ies that reported this information, the sampling interval 
across the 13 studies were from 2002 to 2012 (Table 2).
General characteristics of the included studies
The included studies incorporated patients with 
advanced cancers who had undergone palliative CT. Sam-
ple sizes ranged from 40 [22] to 2313 [23] participants 
Number of studies found in PubMed, 
Scopus, Science direct, Proquest and ISI 
Web of Science databases
n=6930
Number of reviewed studies
n=6930 
Number of studies prior to 
removing of the duplicate studies
n=20
Number of final studies
n=13
Number of studies omitted due to lack of 
inclusion criteria or exclusion criteria
n=6910
Fig. 1 Systematic review search based on PRISMA
Table 1 Number of  articles found from  respective 
databases
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with an age range between 50 and 70  years old. Most 
study participants were male (see Table  3 for demo-
graphic characteristics). Quality of life was measured 
primarily with questionnaires including the Quality of 
Life Questionnaire-C30 (EORTC QLQ-C30), an interna-
tionally validated reliable instrument that evaluates QOL 
in social, role, cognitive, emotional, and physical func-
tioning domains [16, 18, 24]. The European Cooperative 
Oncology Group (ECOG) performance status [3, 4, 16], 
the McGill Quality of Life Questionnaire [25], and Padil-
la’s Quality of Life Index [14] were also used. Other fac-
tors use to evaluate QOL included place of death and use 
of aggressive therapies at end of life [3, 12].
Main outcomes
Prigerson et al. (2015) conducted a prospective, multi-
institution cohort study of patients with end-stage solid 
tumor cancers from different cancer centers across the 
U.S. to determine the relationships between use of CT 
and QOL as patients neared death. Out of 660 patients 
with late stage cancer, 384 died during the study period 
and these patients were evaluated as they approached 
death. Of these patients, 158 (about half, were receiv-
ing CT at study enrollment (4  months median time 
before death). The patients who received CT were sig-
nificantly younger, better educated, had few comorbid 
conditions, had better performance status and were 
more likely to receive treatment at academic cancer 
centers. Further, they were more likely to have either 
breast or pancreatic cancer diagnoses. Findings dem-
onstrated that patients with better performance status 
had a worse quality of death even when controlling for 
intensive care at end of life. For those patients with low 
to moderate performance status, CT use was unrelated 
to quality of death. The researcher’s findings indicated 
that CT use at end of life had no benefits to length of 
survival, and impaired QOL in the patients’ final days 
[4].
A secondary analysis of data from a randomized 
clinical trial evaluating palliative care for patients with 
advanced non-small cell lung cancer were analyzed to 
determine predictors of use of CT in the final two weeks 
of life. Study findings demonstrated that of 125 patients 
who died, 20% (n = 25) had received CT at end of life. Of 
these 25 patients, 15 were receiving oral CT whereas 10 
were receiving intravenous CT or a combination of both 
[25]. Patients who received CT at end of life had worse 
psychological health including significantly more anxiety, 
depressive symptoms, and poorer QOL [25].
Hui and colleagues conducted a retrospective cohort 
study of patients with advanced cancer who died while 
receiving care at a major U.S. Cancer Center. They con-
ducted a comparative analysis of care for 113 patients 
with hematologic malignancies (14% of sample) with 
patients who had solid tumor cancers (n = 816) [16]. The 
patients who died with hematologic malignancies were 
significantly more likely to receive aggressive treatments 
in their final 30 days compared to the group of patients 
with solid tumor cancers. Such care included ICU admis-
sions, CT and targeted therapies, prolonged hospitaliza-
tions, and emergency unscheduled use of services [16] 
that culminated in lower QOL at death.
Table 3 Demographic characteristics of the studied units in the selected studies
a Information not available
















–a 28 –a 55 24 40 Bisht
63 –a 64.5 64 125 151 Fujisawa
1717 6339 55 –a 2313 9768 Groene
–a 182 –a 62 350 816 Hui
7 135 –a 73 9 147 Kao
60 60 66.4 66.4 100 100 Mayrbäurl 2016
59 59 66.2 66.2 104 104 Mayrbäurl 2011
49 190 65 65.5 87 374 Napa
105 105 67.8 67.8 162 162 Pacetti
85 171 56.3 58.6 158 312 Prigerson
119 215 56.4 58.4 216 386 Wright
112 112 67.1 67.1 187 187 Wintner
216 389 –a –a 396 396 Zhang
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In a retrospective cohort study evaluating patients with 
advanced metastatic cancer during their last month of 
life, Pacetti et  al. (2015) found that 162 patients out of 
2164 at a major Italian Oncology Center received CT 
prior to death. Of these patients who received CT in their 
final 30 days, about 65% were males, and the individual 
health provider was the only predictor for why CT was 
continued at end of life [13].
Wright et al. (2014) conducted a secondary analysis of 
data from a large federally funded prospective, longitu-
dinal, multi-institutional study in the U.S. of terminally 
ill patients with advanced cancer. Data from 386 patients 
who died during the study were analyzed to determine 
whether palliative CT administration in the final months 
of life was related to intensity of medical care and loca-
tion of death [3]. Patients who received palliative CT 
(56% of the sample) as compared with those who did not 
receive palliative CT were significantly more likely to 
die in a non-preferred environments, were more likely 
to be hospitalized in an ICU at time of death, and were 
also more likely to receive cardiopulmonary resuscitation 
and/or ventilator support [3].
In a retrospective review study, Kao et al. (2013) evalu-
ated factors associated with use of CT at the end of life 
in Australian patients with malignant mesothelioma. Of 
147 patients who died, 21 received treatment in the last 
month of life [26]. For those patients receiving CT during 
the last month of life, the only factor associated with its’ 
use was having at least two previous cycles of treatment. 
These patients who received CT had significantly shorter 
survival as compared to patients who did not receive CT 
and there was a trend towards death outside the home. 
A limitation of the study was a lack of information about 
where these deaths occurred. Importantly the study sug-
gests that end of life planning is less likely to occur when 
patients continue with CT in the terminal phase of life 
[26].
In a study from Sweden, Nappa and his colleagues 
(2011) evaluated characteristics associated with use of 
palliative CT in patients with advanced stage epithe-
lial cancers in the last month of life. Of 374 patients, 
87 (23%) received palliative CT in the last month of life 
[24]. Use of palliative CT was associated with shorter 
survival, increased hospital admissions, and less likeli-
hood of dying at home. Further, there was less docu-
mented evidence of discussion about ceasing treatment 
with patients who received palliative CT during the last 
month of life.
In a large federally funded longitudinal prospective 
cohort study in the U.S., factors associated with QOL at 
end of life were evaluated in 396 patients with advanced 
cancer and their caregivers. Factors that were most asso-
ciated with lower QOL at end of life included death in 
intensive care and receipt of life-prolonging therapies 
[2]. Better patient QOL was associated with positive rela-
tionships with their physician and pastoral spiritual care 
provision [2]. Other factors that improved QOL at death 
included personal religious activities, caregiver health, 
and better perceived mental health [2].
In another prospective cohort study, Bisht et al. (2011) 
evaluated 40 patients with advanced stage head and neck 
cancer who were receiving palliative care. All patients had 
stage 4 cancer and had recurrence and metastasis to dis-
tant areas. Of the 40 patients, 24 received palliative CT, 
in conjunction with other medications such as analgesics, 
steroids, and anti-emetics for symptom management. 
Findings identified that QOL was positively impacted by 
pharmacologic management of symptoms [22].
Mayrbaurl et al. (2016) conducted a prospective obser-
vational study that evaluated the QOL of 100 patients 
with advanced colorectal cancer who received first, sec-
ond, or third lines of palliative chemotherapy and were 
followed for up to 3 years [27]. At the onset of the study, 
73 patients began first-line of palliative CT, and 27 were 
at the start of second-line palliative CT. Ongoing QOL 
assessment was continued until patients’ were unable to 
complete the questionnaires, death occurred, or the con-
clusion of the 3  year study was completed [27]. Quality 
of life progressively declined with the continuation of 
palliative CT and disease advancement [27]. Mayrbäurl 
et  al. (2012) also conducted a prospective observational 
study at an Austrian health center that compared QOL 
in patients with mixed advanced stage cancer diagno-
ses preparing for palliative CT to healthy age and sex-
matched controls. Quality of life of patients was assessed 
at baseline and during the palliative CT [28] with similar 
comparative lower QOL identified.
Groene and colleagues conducted a prospective pop-
ulation-based observational study of factors associ-
ated with completion of palliative CT in patients with 
advanced esophageal and gastric cancers in England. 
There were 2313 (about 24% of total) patients who 
received palliative CT [23]. Where data were available, 
only 50–60% completed treatment among those with 
good performance status [16]. Findings conclude low 
likelihood of treatment completion (53% overall).
Wintner et  al. (2013) evaluated QOL in patients with 
advanced lung cancer who were receiving varying outpa-
tient palliative CT treatment lines [29]. Findings showed 
that QOL remained essentially unchanged but was worse 
in those receiving advanced lines of CT [18].
Discussion
Given progress in anti-cancer CT strategies for patients 
with advanced cancers, there is an increasing use of pal-
liative CT at the end of life [15].
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The purpose of this study was to evaluate relation-
ships between use of palliative CT and QOL in patients 
with advanced cancer nearing end of life. Generally, the 
results of most of the selected studies indicated that pal-
liative CT was associated with reduced QOL for patients. 
For example, such therapy was associated with increased 
necessity for cardiopulmonary resuscitation, mechanical 
ventilation, use of a feeding tube, and death in intensive 
care [3]. Further, such treatment was also associated with 
shortened survival and reduced quality of death [4].
Some patients with advanced cancer may prefer to 
receive aggressive treatment even if the therapies are 
associated with toxicities and side effects [30]. A study 
by Kao et al. found that patients who received palliative 
CT had shorter survival time and more frequent hospi-
tal admissions including unscheduled emergency depart-
ment visits compared to those who did not receive CT at 
the end of life [26]. The goal of palliative CT is to main-
tain or improve QOL, improve length of survival and 
reduce symptoms in oncologic emergency conditions 
[1]. The usefulness of CT should always be considered 
by associated toxicities and side effects, given potential 
impact on QOL [1]. The presence of adverse effects from 
CT in cancer patients at the end of life was noted in the 
assessed studies [4, 9].
Early provision of palliative care with a multidisci-
plinary team has offered multiple benefits for patients 
with advanced cancer. For example, Temel and her col-
leagues compared two groups of patients who were 
newly diagnosed with metastatic cancer; one group 
that received palliative care with standard oncological 
care and the other group who received only standard 
oncology care. Findings demonstrated that the group 
that received integrated early palliative care had com-
paratively significant improvement in QOL, mood, 
and length of survival [12]. A complex issue is the use 
of palliative CT as a supportive strategy to improve 
length of survival, bolster QOL, assist with symptom 
management, and reduce disease progression given it 
may also result in more aggressive care at end of life [8]. 
Regimens and types of CT used in the palliative con-
text vary. Further, it is often not clear that patients’ who 
receive these treatments have clearly addressed their 
end of life wishes and have advanced directives in place. 
Patients may die while receiving anti-cancer regimens 
because of death denial and/or communication barri-
ers with their oncology team. For example, it may be 
more challenging to discuss stoppage of treatment as 
opposed to recommending further CT for patients who 
are nearing end of life [8] especially when patients are 
younger and have reasonable performance status. The 
mental health of patients at end of life and communi-
cation with their health providers may also impact the 
type of decisions patients will make in regards to sus-
taining treatment [31]. Without clear guidelines, the 
continued problems with medically futile treatments 
and untoward deaths in highly costly and non-preferred 
environments are likely to persist.
The review has limitations. These limitations include 
the possibility that articles that pertain to use of CT at 
end of life in patients with cancer were missed. For 
example, some studies may not include oral CT when 
evaluating use of CT at end of life [18]. Further, given 
the complex issues associated with patients who have 
advanced cancers, e.g., age, developmental stage, type 
of disease, comorbid conditions, etc., it can be chal-
lenging to determine best approaches to optimize indi-
vidualized care at end of life. Cultural factors including 
the role of family caregivers may impact whether or not 
palliative CT is offered and utilized, and whether or not 
death occurs in a preferred environment. More research 
is needed that examines such issues across cultures, espe-
cially as more types of CT are made available to patients 
with advanced cancers. Research that includes diverse 
samples from global samples remains needed. Many of 
the current studies were conducted at major tertiary can-
cer centers so may not be reflective of practices in non-
urban communities. Another limitation relates to the lag 
in sampling intervals among the published papers (2002–
2012). Studies with more recent data collection could 
better reflect current practices.
Conclusions
The results of most selected studies show that palliative 
CT is associated with a decrease in QOL for patients. 
However, studies have been conducted primarily in Euro-
pean and American countries, and patients’ cultural 
backgrounds may affect quality of life at the end of life. 
More research is needed in developing countries, includ-
ing the Middle East and Asia.
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